[go: up one dir, main page]

PE20080695A1 - Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel - Google Patents

Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel

Info

Publication number
PE20080695A1
PE20080695A1 PE2007000511A PE2007000511A PE20080695A1 PE 20080695 A1 PE20080695 A1 PE 20080695A1 PE 2007000511 A PE2007000511 A PE 2007000511A PE 2007000511 A PE2007000511 A PE 2007000511A PE 20080695 A1 PE20080695 A1 PE 20080695A1
Authority
PE
Peru
Prior art keywords
phenyl
dihydropirazolopyrimidinone
derivatives
inhibitors
alyl
Prior art date
Application number
PE2007000511A
Other languages
English (en)
Inventor
Makoto Bamba
Hidetomo Furuyama
Hiroshi Hirai
Kenji Niiyama
Toshihide Nishibata
Sachie Otsuki
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38655640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080695(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of PE20080695A1 publication Critical patent/PE20080695A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DIHIDROPIRAZOLOPIRIMIDINONA DE FORMULA (I), EN DONDE A ES DE FORMULA (aa1); R1C ES H, ALQUENILO INFERIOR O Q3-A3(R1d)R1e; DONDE A3 ES N; METINO O 1-VINIL-2-ILDENO; Q3 ES UN ENLACE O ALQUILENO INFERIOR; R1d Y R1e SON INDEPENDIENTEMENTE H, HALOGENO, CN, HIDROXILO, ENTRE OTROS; R1 ES ALQUENILO O ALQUINILO INFERIOR; R2 ES FENILO, PIRIDILO O TIENILO EL CUAL PUEDE TENER UN GRUPO A4(R1g)R1h; R5 y R6 SON H, ALQUILO INFERIOR O HIDROXIALQUILO INFERIOR. SON SELECCIONADOS: 3-(2-ALIL-6-{[4-(4-METILPIPERAZIN -1-IL)FENIL]AMINO}-3-OXO-1,2-DIHIDRO-3H-PIRAZOLO[3,4-d]PIRIMIDIN-1-IL)-N,N-DIMETILBENZAMIDA, 2-ALIL-1-[3-(1-HIDROXI-1-METILETIL)FENIL]-6-{[4-(4-METILPIPERAZIN-1-IL)FENIL]AMINO}-1,2-DIHIDRO-3H-PIRAZOLO[3,4-d]PIRIMIDIN-3-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE QUINASA WEEL Y SON UTILES EN EL TRATAMIENTO DE DIVERSOS CANCERES
PE2007000511A 2006-04-27 2007-04-24 Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel PE20080695A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006124208 2006-04-27

Publications (1)

Publication Number Publication Date
PE20080695A1 true PE20080695A1 (es) 2008-06-28

Family

ID=38655640

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000511A PE20080695A1 (es) 2006-04-27 2007-04-24 Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel

Country Status (38)

Country Link
US (4) US7834019B2 (es)
EP (2) EP2016080B1 (es)
JP (2) JP4513919B2 (es)
KR (1) KR101409161B1 (es)
CN (1) CN101432284B (es)
AR (1) AR060635A1 (es)
AT (1) ATE475662T1 (es)
AU (1) AU2007244185B2 (es)
BR (1) BRPI0710081A2 (es)
CA (1) CA2650119C (es)
CR (1) CR10359A (es)
CY (2) CY1111069T1 (es)
DE (1) DE602007008085D1 (es)
DK (2) DK2016080T3 (es)
DO (1) DOP2007000084A (es)
EC (1) ECSP088812A (es)
ES (2) ES2609087T3 (es)
GT (1) GT200800211A (es)
HN (1) HN2008001532A (es)
HR (2) HRP20161763T1 (es)
HU (1) HUE032987T2 (es)
IL (1) IL194367A (es)
LT (1) LT2017278T (es)
MA (1) MA30428B1 (es)
MX (1) MX2008013063A (es)
MY (1) MY145408A (es)
NO (1) NO341617B1 (es)
NZ (1) NZ571196A (es)
PE (1) PE20080695A1 (es)
PL (2) PL2016080T3 (es)
PT (2) PT2017278T (es)
RU (1) RU2437885C2 (es)
SI (2) SI2017278T1 (es)
SV (1) SV2009003060A (es)
TW (1) TWI409262B (es)
UA (1) UA96152C2 (es)
WO (2) WO2007126128A1 (es)
ZA (1) ZA200807748B (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
EP2155752B1 (en) * 2007-04-25 2018-09-19 Merck Sharp & Dohme Corp. Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor
WO2008141385A1 (en) * 2007-05-21 2008-11-27 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
EP2213673B1 (en) * 2007-10-23 2013-06-05 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
US8507504B2 (en) 2008-06-12 2013-08-13 Merck Sharp & Dohme Corp. Process for producing bicycloaniline derivatives
WO2010067888A1 (en) * 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivatives
WO2010076887A1 (en) * 2009-01-05 2010-07-08 Banyu Pharmaceutical Co.,Ltd. Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
JP2012518598A (ja) * 2009-02-25 2012-08-16 Ｍｓｄ株式会社 ピリミドピリミドインダゾール誘導体
EP2473633A4 (en) * 2009-09-02 2013-03-06 Msd Kk USE OF ONE OR MORE BIOMARKERS TO IDENTIFY A WEE1 DISEASED PATIENT AND PROCEDURE FOR TREATING CANCER MEDIATED BY DYSFUNCTIONAL OR ABERRANT P53 BY ADMINISTERING A WEE1 HEMMER
PL2477628T3 (pl) 2009-09-15 2015-02-27 Merck Sharp & Dohme Wytwarzanie krystalicznych hemihydratowych postaci dihydropirazolopirymidynonu
CN103442710B (zh) 2010-11-16 2018-05-29 阵列生物制药公司 检测点激酶1抑制剂和wee1激酶抑制剂的组合
KR102093947B1 (ko) * 2011-04-27 2020-03-26 제온 코포레이션 중합성 화합물, 중합성 조성물, 고분자, 및 광학 이방체
WO2013013031A1 (en) * 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
WO2013039854A1 (en) 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
JP2014530867A (ja) * 2011-10-20 2014-11-20 アッヴィ・インコーポレイテッド キナーゼのピリドピリミジノン阻害剤
ES2606640T3 (es) * 2012-02-23 2017-03-24 Abbvie Inc. Inhibidores de cinasas de tipo piridopirimidinona
WO2014062454A1 (en) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
PL2925888T3 (pl) * 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
JP2016516772A (ja) 2013-04-09 2016-06-09 リクスト・バイオテクノロジー，インコーポレイテッド オキサシクロヘプタン及びオキサビシクロヘプテンの配合物
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
US10293019B2 (en) * 2014-12-17 2019-05-21 Delta-Fly Pharma, Inc. Pharmaceutical composition for treatment of or remission in elderly or terminal cancer patient
WO2016168633A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
AR104293A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
CN108349981B (zh) * 2015-09-01 2021-03-30 大鹏药品工业株式会社 新型的吡唑并[3，4－d]嘧啶化合物或其盐
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
US10947238B2 (en) * 2015-11-01 2021-03-16 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of making and using the same
GB201612092D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
MA46229B1 (fr) 2016-09-15 2020-10-28 Boehringer Ingelheim Int Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
CN106719769A (zh) * 2016-11-28 2017-05-31 山东农业大学 一种含香菇多糖、苯醚甲环唑和噻虫啉的病虫兼治农药组合物
EP3551629B1 (en) 2016-12-08 2023-11-15 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
ES2902050T3 (es) * 2017-01-23 2022-03-24 Shijiazhuang Sagacity New Drug Dev Co Ltd Derivado 1,2-dihidro-3H-pirazolo[3,4-D]pirimidin-3-ona como inhibidor de Wee1
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
WO2018171633A1 (zh) * 2017-03-23 2018-09-27 上海迪诺医药科技有限公司 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
CN110678169A (zh) 2017-03-31 2020-01-10 西雅图遗传学公司 Chk1-抑制剂与weel-抑制剂的组合
KR20200034781A (ko) * 2017-08-01 2020-03-31 리커리엄 아이피 홀딩스, 엘엘씨 1,2-다이하이드로-3H-피라졸로[3,4-d]피리미딘-3-온 유사체
WO2019037678A1 (zh) * 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
EP3694509A4 (en) 2017-10-09 2021-07-14 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
WO2019085933A1 (zh) 2017-11-01 2019-05-09 南京明德新药研发股份有限公司 作为Wee1抑制剂的大环类化合物及其应用
WO2019096322A1 (zh) * 2017-11-20 2019-05-23 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
WO2019134539A1 (zh) * 2018-01-05 2019-07-11 四川科伦博泰生物医药股份有限公司 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
US11479555B2 (en) * 2018-02-23 2022-10-25 Newave Pharmaceutical Inc. Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
WO2019169065A2 (en) * 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
CN117720541A (zh) * 2018-03-09 2024-03-19 里科瑞尔姆Ip控股有限责任公司 取代的1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮
CN108653282B (zh) * 2018-06-28 2020-08-14 中国科学院昆明植物研究所 苯并噻唑类及苯并吡咯类化合物在制备抗肿瘤药物中的应用
WO2020083404A1 (zh) * 2018-10-26 2020-04-30 南京明德新药研发有限公司 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
CN111662283B (zh) * 2019-03-07 2021-11-16 湖南化工研究院有限公司 咪唑并吡啶类化合物及其中间体、制备方法与应用
EP3943496A4 (en) * 2019-03-22 2022-05-18 Shouyao Holdings (Beijing) Co., Ltd. Wee1 inhibitor and preparation and use thereof
MX2021012418A (es) 2019-04-09 2021-11-12 Nuvation Bio Inc Compuestos heterociclicos y sus usos.
EP3952875A4 (en) * 2019-04-09 2022-12-28 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
RS65747B1 (sr) 2019-04-30 2024-08-30 Wuxi Biocity Biopharmaceutics Co Ltd Kristalni oblik jedinjenja inhibitora wee1 i njegova upotreba
MX2021015572A (es) * 2019-06-28 2022-04-06 Shanghai Pharmaceuticals Holding Co Ltd Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones.
CN112142748B (zh) 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
BR112022007609A2 (pt) 2019-10-25 2022-07-19 Astrazeneca Ab Métodos para tratar o câncer
WO2021127047A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
CN113387962A (zh) * 2020-03-12 2021-09-14 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2021254389A1 (zh) * 2020-06-17 2021-12-23 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡唑并[3，4-d]嘧啶-3-酮衍生物
KR102549484B1 (ko) * 2020-12-08 2023-06-29 한국화학연구원 피라졸로피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 관련 질환의 예방 또는 치료용 약학적 조성물
CN116848118A (zh) * 2021-02-09 2023-10-03 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物
CN116867787A (zh) * 2021-02-09 2023-10-10 微境生物医药科技(上海)有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022171126A1 (zh) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
CN115197221B (zh) * 2021-04-02 2024-05-24 轩竹(北京)医药科技有限公司 二氢吡唑并嘧啶酮类大环衍生物及其用途
AU2022265718A1 (en) 2021-04-29 2023-11-02 Novartis Ag Deubiquitinase-targeting chimeras and related methods
BR112023022236A2 (pt) 2021-04-30 2024-02-06 Wigen Biomedicine Tech Shanghai Co Ltd Composto de fórmula geral (1) ou seu isômero, forma cristalina, sal farmaceuticamente aceitável, hidrato ou solvato; composição farmacêutica; e; uso do composto ou seu isômero, forma cristalina, sal farmaceuticamente aceitável, hidrato ou solvato
EP4349838A4 (en) 2021-05-28 2025-08-13 Jiangsu Tasly Diyi Pharmaceutical Co Ltd WEE1 INHIBITOR AND ITS USE
TW202328142A (zh) * 2021-09-18 2023-07-16 香港商優領醫藥科技(香港)有限公司 含嘧啶并二氫吡唑啉酮類衍生物、其藥學上可接受的鹽及其製備方法和應用
CN113880844B (zh) * 2021-09-29 2023-02-14 武汉九州钰民医药科技有限公司 Wee1蛋白激酶抑制剂adavosertib的化学合成方法
CN113735863A (zh) * 2021-09-29 2021-12-03 武汉九州钰民医药科技有限公司 Wee1抑制剂adavosertib的制备工艺
TW202322812A (zh) * 2021-11-01 2023-06-16 大陸商正大天晴藥業集團股份有限公司 吡唑［３，４－ｄ］嘧啶－３－酮類化合物、包含其的藥物組合物及其醫藥用途
CN116462687B (zh) * 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN115073460B (zh) * 2022-07-13 2023-07-25 苏州施安鼎泰生物医药技术有限公司 一种嘧啶并[5,4-c][2,6]萘啶衍生物及其制备方法以及药物组合物和应用
TW202404977A (zh) * 2022-07-15 2024-02-01 大陸商映恩生物製藥（蘇州）有限公司 一種嘧啶并五員雜環化合物、其製備方法和用途
CN119798282A (zh) * 2023-10-11 2025-04-11 智擎生技制药股份有限公司 基于稠合吡啶环的Myt1抑制剂
TW202519226A (zh) 2023-11-08 2025-05-16 美商艾克塞里克斯公司 使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2628707B2 (ja) * 1987-08-26 1997-07-09 三井製薬工業株式会社 ピリミジン類及びその薬学的に許容される塩類
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
CZ51593A3 (en) 1990-09-28 1994-01-19 Smithkline Beecham Corp Water-soluble analogs of camptothecine, process of their preparation and use
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
HU221343B1 (en) 1992-10-28 2002-09-28 Genentech Inc Use of anti-vegf antibodies for the treatment of cancer
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
JP2006504632A (ja) 2002-04-26 2006-02-09 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー チェックポイントキナーゼ（Ｗｅｅ１およびＣｈｋ１）の阻害剤
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
BRPI0406809A (pt) 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
US7407962B2 (en) * 2003-02-07 2008-08-05 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors or protein kinases
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050250836A1 (en) 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
PL1775298T3 (pl) 2004-07-01 2013-08-30 Daiichi Sankyo Co Ltd Pochodna tienopirazolowa wykazująca aktywność hamowania PDE7
EP1846408B1 (en) 2005-01-14 2013-03-20 Janssen Pharmaceutica NV 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer

Also Published As

Publication number Publication date
EP2017278A4 (en) 2009-04-22
TWI409262B (zh) 2013-09-21
CY1111069T1 (el) 2012-05-23
IL194367A0 (en) 2009-08-03
KR20090017491A (ko) 2009-02-18
UA96152C2 (en) 2011-10-10
ATE475662T1 (de) 2010-08-15
EP2016080B1 (en) 2010-07-28
SI2017278T1 (sl) 2017-05-31
AR060635A1 (es) 2008-07-02
WO2007126122A1 (en) 2007-11-08
CR10359A (es) 2009-02-19
HK1132498A1 (en) 2010-02-26
DK2016080T3 (da) 2010-11-22
EP2017278A1 (en) 2009-01-21
JP4513919B2 (ja) 2010-07-28
NO20084968L (no) 2008-11-26
SI2016080T1 (sl) 2011-03-31
HN2008001532A (es) 2009-06-10
PL2017278T3 (pl) 2017-10-31
PT2017278T (pt) 2017-01-03
IL194367A (en) 2014-12-31
DOP2007000084A (es) 2007-12-31
GT200800211A (es) 2009-04-07
NO341617B1 (no) 2017-12-11
EP2016080A1 (en) 2009-01-21
HUE032987T2 (en) 2017-11-28
WO2007126128A1 (ja) 2007-11-08
RU2437885C2 (ru) 2011-12-27
AU2007244185A1 (en) 2007-11-08
MY145408A (en) 2012-02-15
US20100063024A1 (en) 2010-03-11
BRPI0710081A2 (pt) 2011-08-02
NZ571196A (en) 2011-03-31
US20140303178A1 (en) 2014-10-09
EP2016080A4 (en) 2009-05-13
CA2650119A1 (en) 2007-11-08
CA2650119C (en) 2017-03-14
JPWO2007126128A1 (ja) 2009-09-17
CN101432284A (zh) 2009-05-13
AU2007244185B2 (en) 2012-10-04
US20070254892A1 (en) 2007-11-01
US20110189130A1 (en) 2011-08-04
ES2348751T3 (es) 2010-12-13
US7935708B2 (en) 2011-05-03
DE602007008085D1 (en) 2010-09-09
HRP20100563T1 (hr) 2010-11-30
US7834019B2 (en) 2010-11-16
TW200811176A (en) 2008-03-01
KR101409161B1 (ko) 2014-06-19
US8791125B2 (en) 2014-07-29
ECSP088812A (es) 2008-11-27
ZA200807748B (en) 2009-10-28
ES2609087T3 (es) 2017-04-18
SV2009003060A (es) 2009-04-28
PL2016080T3 (pl) 2011-03-31
HRP20161763T1 (hr) 2017-02-24
LT2017278T (lt) 2017-01-25
MA30428B1 (fr) 2009-05-04
RU2008146759A (ru) 2010-06-10
JP5167291B2 (ja) 2013-03-21
DK2017278T3 (en) 2017-02-13
CN101432284B (zh) 2012-08-15
JP2010132689A (ja) 2010-06-17
CY1118526T1 (el) 2017-07-12
MX2008013063A (es) 2008-12-16
EP2017278B1 (en) 2016-11-02
PT2016080E (pt) 2010-10-14

Similar Documents

Publication Publication Date Title
PE20080695A1 (es) Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
PE20080944A1 (es) Derivados de pirimidina como inhibidores del receptor de cinasa activina(alk-5)
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20220597A1 (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
PE20090718A1 (es) Derivados de espiroindolinona
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20090741A1 (es) Derivados de 1,1,1-trifluor-2-hidroxi-3-fenilpropano
PE20070004A1 (es) Imidazoquinolinas como inhibidores de quinasa de lipido
PE20081447A1 (es) Compuestos y composiciones como inhibidores de la proteina cinasa
TR201906123T4 (tr) P13 kinazı ve mtor inhibitörleri olarak triazin bileşikleri.
PE20090902A1 (es) Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
PE20091116A1 (es) Derivados de piridina y pirazina como inhibidores de tirosina quinasas
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
PE20110153A1 (es) Derivados de piridazina como inhibidores de smo
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
PE20080275A1 (es) Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa
PE20071138A1 (es) Derivados de pirimidina como inhibidores de quinasas
PE20091527A1 (es) Derivados de piridazinona
PE20081831A1 (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona

Legal Events

Date Code Title Description
FG Grant, registration